Navigation Links
Study Shows Velcade Plus Doxil Improves Survival in Previously,Treated Patients With Multiple Myeloma

Data Presented at the ASCO Cancer Conference

NORTH HOLLYWOOD, Calif., and CHICAGO, June 04, 2007 /PRNewswire/ -- The International Myeloma Foundation (IMF)-supporting research and providing education, advocacy and support for myeloma patients, families, researchers and physicians-today said that data from a follow-up to a Phase 3 multi- national clinical trial shows the combination of DOXIL(R) with VELCADE(R) improves the probability of survival by 41%. The follow-up study also showed no increase in serious side effects such as neuropathy with the addition of DOXIL to the VELCADE. The findings were presented at the American Society of Clinical Oncology (ASCO) global cancer meeting in Chicago.

The VELCADE/DOXIL combination was approved by the FDA just last month as a new treatment option for myeloma patients who have relapsed or who have not responded to at least one other course of treatment. The drugs work in combination because there is evidence that VELCADE increases the effectiveness of DOXIL against cancer cells and DOXIL does the same for VELCADE.

"'Improved survival' are words that every cancer patient wants to hear, and we are encouraged to have this new option to offer patients with peer reviewed data behind it," said Susie Novis, president and co-founder of the IMF. "Until there is a cure, we are moving myeloma toward becoming a chronic disease with long term survival achieved by using drugs in combination and in sequence. The VELCADE/DOXIL combination fits perfectly into this paradigm and offers an important and powerful new opportunity to extend and improve patients' lives."

DOXIL is a specially (liposomal) formulated version of the chemotherapy agent doxorubicin, and is approved for use in other forms of cancer. VELCADE, bortezomib, is approved for myeloma patients who have relapsed or not responded to a previous course of treatment. The findings come from a 14 month follow-up
'"/>




Page: 1 2

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:5/9/2008)...USNewswire/ -- Osteoarthritis is a,painful and pot...t 50,million people in the United States. It is ca... The novel investigational pain medication,tapenta...ignificant relief,for patients with joint-disease ...with fewer gastrointestinal side effects than thos...
(Date:5/9/2008)...ewswire/ -- The risk of the two major,prostate dis...H), can be,reduced by changes in lifestyle, such a...d eating a healthy diet. Alan Kristal, Dr.P.H., as...red Hutchinson Cancer Research,Center in Seattle, ...ot,feel helpless against prostate cancer or BPH.,...
(Date:5/9/2008)...Study Shows Positive Results with X-ray ... /- Roche today announced one-year,re...that ACTEMRA(TM),(tocilizumab) can significantly i...in patients with rheumatoid arthritis (RA), a crit...The study also demonstrated that ACTEMRA,reduces d...
(Date:5/8/2008)...lobus Medical, Inc., the largest,privately held sp...nized,leader in motion preservation technology, to...SECURE(R)-C Cervical Artificial Disc IDE study. Th...al motion of the spine in,order to alleviate pain ...n,the treatment of symptomatic cervical disc disea...
Breaking Medicine Technology:Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 2Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 3Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 4Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 5Preventing Prostate Cancer and BPH: Prostate-Health Expert Available (National Men's Health Week Is June 9-15) 2Preventing Prostate Cancer and BPH: Prostate-Health Expert Available (National Men's Health Week Is June 9-15) 3Preventing Prostate Cancer and BPH: Prostate-Health Expert Available (National Men's Health Week Is June 9-15) 4New Study Demonstrates ACTEMRA(R) (tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients 2New Study Demonstrates ACTEMRA(R) (tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients 3New Study Demonstrates ACTEMRA(R) (tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients 4New Study Demonstrates ACTEMRA(R) (tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients 5Globus Medical Completes Enrollment Of SECURE(R)-C Cervical Artificial Disc Clinical Trial 2Mislabeled Supplement Spurred Prostate Cancer 3A Report 9792 1Mislabeled Supplement Spurred Prostate Cancer 3A Report 9792 2Mislabeled Supplement Spurred Prostate Cancer 3A Report 9792 3Gift of Life Celebrates Saving Lives and Setting Records in 2007 9788 1Gift of Life Celebrates Saving Lives and Setting Records in 2007 9788 2Gift of Life Celebrates Saving Lives and Setting Records in 2007 9788 3Cardica to Announce Fiscal 2008 Second Quarter Financial Results on Thursday January 24 2008 9784 1Cardica to Announce Fiscal 2008 Second Quarter Financial Results on Thursday January 24 2008 9784 2In response to a New England Journal of Medicine article published yesterday and subsequent media coverage Eli Lilly and Company issued the following 2665 1In response to a New England Journal of Medicine article published yesterday and subsequent media coverage Eli Lilly and Company issued the following 2665 2In response to a New England Journal of Medicine article published yesterday and subsequent media coverage Eli Lilly and Company issued the following 2665 3In response to a New England Journal of Medicine article published yesterday and subsequent media coverage Eli Lilly and Company issued the following 2665 4
(Date:5/12/2008)...O, May 12 /PRNewswire-FirstCall/ - Med-Emerg Inter... revenue from continuing operations,for the three...pared to,$4.8 million for the same period in 2007 ... the three month period, earnings before,depreciat...roved to $179K,from a loss of ($106K) in 2007. The...
(Date:5/12/2008)...D, Calif., May 12 /PRNewswire-FirstCall/ -- (Nasda...Heart" or the "Corporation") announced,that the To...ay advising it,is reviewing the eligibility for co... WorldHeart under sections 709 and 710(a) of the T...any,s financial condition and,operating results, m...
(Date:5/12/2008)...ONT, Calif., May 12 /PRNewswire/ -- Keck Graduate ...008, commencement ceremony will feature,the gradua...tudent, Eric,Tan, and the unveiling of KGI,s first... of Eric,s achievement in becoming the,first gradu..., KGI,s senior,vice president for academic affairs...
(Date:5/12/2008)...LE, N.Y., May 12 /PRNewswire/ -- Fairbank Farms, a...tary recall of selected ground beef,products produ...gh Price,Chopper, Shaw,s, BJ,s, and Wilson Farms r... affected product may contain small pieces of hard...l-by" date of 05/13/08, 05/15/08, or a,"Julian dat...
Breaking Medicine News(10 mins):Health News:Med-Emerg International Inc. reports improved income from continuing operations 2Health News:Med-Emerg International Inc. reports improved income from continuing operations 3Health News:WorldHeart Notified of TSX Delisting Review 2Health News:KGI 2008 Commencement Features First PhD Graduate, Biotech Painting 2Health News:Fairbank Farms Issues Voluntary Recall for Selected Ground Beef Products 2
...ople with inhalation anthrax is needed to minimize...nguishing // someone who has anthrax from someone ...tory-related illness is the question that has rema...earchers in Chicago set out to answer .They compar...
...ptoms of osteoarthritis the major cause of disabil...w weeks // say researchers according to a recent s...nes in Europe and the United States recommend the ...oidal anti-inflammatory drugs to relieve osteoarth...
... mass that can lead to an increased risk of fractu...y // bone mineral density testing. New drugs and m...ing of osteoporosis. Researchers looked at the tre...988 to 2003.They reported that the number of physi...
... trial of people infected with both HIV and hepati...ing to their study, patients who are treated with ...e likely to rid their bodies of HCV than those who...s important because as many as 300,000 of the esti...
Other Medicine News:
The KM-500's unique viewing and alignment window lets you observe the targeted eye from any distance. Two rechargeable batteries provide continuous uninterrupted use. Each battery provides 60 minutes
Non-dissolvable Herrick Lacrimal Plugs provide long-term lacrimal occlusion through partial blockage of the horizontal canaliculus.
Provides quick freezing and quick defrosting by reversible flow of gas system - cleans the probes for every cycle automatically. Lightweight probe tips have high conductivity silver. Useful for Catar
...y reversible flow of gas system - cleans the probe... tips have high conductivity silver. Single footsw...r of the two by a simple selector switch. Surgeon ...and Aspiration together with the double footswitch...
Medicine Products: